SLC5A2 and type 2 diabetes mellitus: SGLT2 inhibitors have the potential to reduce CV risk in patients with T2DM [25, 26] not only through beneficial effects on glycemic control but also via beneficial effects on body weight, BP, lipids, and serum uric acid [27, 28].